摘要
目的探讨伏立康唑治疗慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)合并肺部真菌感染的临床效果及对炎性因子水平的影响。方法回顾性分析宿迁市第一人民医院2016年4月至2018年4月收治的80例拟诊COPD合并肺部真菌感染患者的临床资料,将其中采用伊曲康唑治疗的40例患者纳入对照组,采用伏立康唑治疗的40例患者纳入试验组。比较两组患者临床症状好转时间,采用酶联免疫吸附测定检测两组患者治疗前后血清炎性因子[肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、白介素(interleukin,IL)-10、IL-4及IL-12]水平,比较两组患者临床疗效和不良反应发生情况。结果试验组患者各临床症状好转时间均显著短于对照组(P均<0.05),治疗总有效率显著高于对照组(P <0.05);两组患者不良反应总发生率比较无显著差异(P> 0.05)。治疗后试验组患者TNF-α和IL-12水平均显著低于对照组(P_均<0.05),IL-10和IL-4水平均显著高于对照组(P_均<0.05)。结论伏立康唑治疗COPD合并肺部真菌感染疗效较好,且安全性较高,在严格控制不良反应的情况下,适合推广使用。
Objective To investigate the clinical effects of Voriconazole in patients with chronic obstructive pulmonary disease(COPD)combined with fungal infection and its effect on the levels of inflammatory factors.MethodRetrospectively analyzed the clinical data of80patients with suspected COPD combined with fungal infection admitted to the First People's Hospital of Suqian City from April2016to April2018.Among them,40patients treated with Itraconazole were enerolled into control group,40patients treated with Voriconazole were enerolled into experimental group.The improvement time of clinical symptoms was observed.The levels of serum inflammatory factors[tumor necrosis factor-α(TNF-α),interleukin(IL)-10,IL-4and IL-12]were measured by ELISA before and after treatment.The clinical efficacy and adverse reactions were compared between the two groups.ResultThe improvement time of each symptom in experimental group was significantly shorter than that in control group(Pall<0.05),the total effective rate was significantly higher than that of control group(P<0.05).There was no significant difference in the total incidence of adverse reaction between the two groups(P>0.05).After treatment,the levels of TNF-αand IL-12in experimental group were significantly lower than those in control group(Pall<0.05),and the levels of IL-10and IL-4were significantly higher than those in control group(Pall<0.05).ConclusionVoriconazole is effective in the treatment of COPD combined with pulmonary fungal infection with high clinical efficacy and high safety.It is suitable for popularization in the case of strict control of adverse reactions.
作者
张新静
陆小威
苏佳
朱际平
ZHANG Xin-jing;LU Xiao-wei;SU Jia;ZHU Ji-ping(Department of Respiratory,First People's Hospital of Suqian City,Jiangsu,Suqian 223800,China;Department of Respiratory,Affiliated Hospital of Nanjing University of TCM,Jiangsu Province Hospital of TCM,Nanjing 210029,China)
出处
《中国医学前沿杂志（电子版）》
2018年第12期29-32,共4页
Chinese Journal of the Frontiers of Medical Science(Electronic Version)
基金
国家自然科学基金(81774080)
关键词
伏立康唑
感染
真菌
慢性阻塞性肺疾病
炎性因子
Voriconazole
Infection
Fungus
Chronic obstructive pulmonary disease
Inflammatory factor
